NYSE : BSX

Boston Scientific Corporation

$45.51 USD

$1.26 (2.85%)

Volume
20.03M
Average Volume
20.16M
Market Capitalization
$67.64B
P/E Ratio
18.96
Dividend Yield
0.00%
Price Target
$70.00
Year High
$109.50
Year Low
$42.20
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.90
Company Overview

NYSE

Michael F. Mahoney

Medical - Devices

Healthcare

BSX

59000

US

USD

https://www.bostonscientific.com

508 683 4000

101137107

0000885725

Liquidity Metrics

0.43

1.90

1.22

0.33

0.00

Sales & Valuation

$20.07B

3.28

2.61

19.65

2.32

Profitability

$1.94

$2.89B

17.24%

18.15%

14.82%

8.01%

P/E Metrics

18.96

0.26

0.26

Analyst Price Target & Rating

$70.00

$120.00

$55.00

Neutral

3/5

44 Analysts

-34.99%

Financial Health Scores

3.27

7/9

$4.11B

$44.35B

$18.25B

$4.26B

Key Metrics (TTM)

$75.28B

3.65

13.30

1.90

14.82%

9.90%

5.41%

5.23%

$30.62

172 days

Company Executives
Name Title
Adam Smith General Manager of Global Sales & Marketing
Arthur Crosswell Butcher Executive Vice President and Group President of MedSurg & Asia Pacific
Paudie O'Connor Executive Vice President of Global Operations
Brenda Becker Senior Vice President of Global Government Affairs
Emily Woodworth Senior Vice President, Global Controller & Chief Accounting Officer
Miriam O'sullivan Senior Vice President & Chief Human Resources Officer
Joseph Fitzgerald Executive VP & Group President of Cardiovascular
Jonathan Monson Executive Vice President & Chief Financial Officer
Michael F. Mahoney Chairman, President & Chief Executive Officer
Vance R. Brown EVP, General Counsel & Corporate Secretary
Poll Results

No votes yet today — be the first to share your view!

About Boston Scientific Corporation (NYSE:BSX) Stock

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management ... systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Delta Global Management LP Purchases Shares of 28,012 Boston Scientific Corporation $BSX

2026-07-27 04:45:12

Delta Global Management LP acquired a new position in Boston Scientific Corporation (NYSE: BSX) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 28,012 shares of the medical equipment provider's stock, valued at approximately $1,758,000. Several other hedge funds and other institutional investors have also

Boston Scientific (BSX) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

2026-07-24 10:16:17

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

Bank of Nova Scotia Increases Holdings in Boston Scientific Corporation $BSX

2026-07-24 03:59:51

Bank of Nova Scotia raised its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 15.5% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,303,011 shares of the medical equipment provider's stock after acquiring an additional 308,930 shares during

Boston Scientific Corporation $BSX Shares Sold by Baader Bank Aktiengesellschaft

2026-07-22 06:11:01

Baader Bank Aktiengesellschaft decreased its holdings in Boston Scientific Corporation (NYSE: BSX) by 50.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,770 shares of the medical equipment provider's stock after selling 12,014 shares during the

Andra AP fonden Boosts Stake in Boston Scientific Corporation $BSX

2026-07-22 04:53:42

Andra AP fonden lifted its holdings in Boston Scientific Corporation (NYSE: BSX) by 144.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,928 shares of the medical equipment provider's stock after purchasing an additional 100,406 shares during

Bessemer Group Inc. Sells 3,851,493 Shares of Boston Scientific Corporation $BSX

2026-07-22 03:44:09

Bessemer Group Inc. reduced its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 98.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,473 shares of the medical equipment provider's stock after selling 3,851,493 shares during the quarter. Bessemer

Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know

2026-07-21 19:01:14

Boston Scientific (BSX) reached $43.19 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.

Artisan Value Fund Q2 2026 Portfolio Update

2026-07-21 11:25:00

US equities advanced during Q2, supported by another quarter of better-than-expected corporate earnings and continued enthusiasm for companies benefiting from artificial intelligence-related investment. Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Our top five contributors to return in Q2 were Texas Instruments, Lam Research, NXP Semiconductors, Elevance Health and Alphabet.

Frequently Asked Questions

What is the current Boston Scientific Corporation (BSX) stock price?

Boston Scientific Corporation(NYSE:BSX) stock price is $45.51 in the last trading session. During the trading session, BSX stock reached the peak price of $109.5 while $42.2 was the lowest point it dropped to. The percentage change in BSX stock occurred in the recent session was 2.85% while the dollar amount for the price change in BSX stock was $1.26.

BSX's industry and sector of operation?

The NYSE listed BSX is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of BSX?

Adam Smith | General Manager of Global Sales & Marketing
Arthur Crosswell Butcher | Executive Vice President and Group President of MedSurg & Asia Pacific
Paudie O'Connor | Executive Vice President of Global Operations
Brenda Becker | Senior Vice President of Global Government Affairs
Emily Woodworth | Senior Vice President, Global Controller & Chief Accounting Officer

How many employees does BSX have?

Number of BSX employees currently stands at 59000. BSX operates from 300 Boston Scientific Way, Marlborough, MA 01752-1234, US.

Link for BSX official website?

Official Website of BSX is: https://www.bostonscientific.com

How do I contact BSX?

BSX could be contacted at phone #508 683 4000 and can also be accessed through its website. BSX operates from 300 Boston Scientific Way, Marlborough, MA 01752-1234, US.

How many shares of BSX are traded daily?

The average number of BSX shares traded daily for last 3 months was 20.16M.

What is the market cap of BSX currently?

The market value of BSX currently stands at $67.64B with its latest stock price at $45.51